Patents by Inventor Serge CAMELO

Serge CAMELO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds targeting the eye and use thereof in the treatment of eye diseases
    Patent number: 12215067
    Abstract: Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: February 4, 2025
    Assignees: BIOPHYTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Laurence Dinan, René Lafont, Pierre Dilda, Serge Camelo, Valérie Fontaine, Christine Balducci, Elodie Monteiro, Louis Guibout, Mathilde Latil, José-Alain Sahel, Stanislas Veillet
  • PHYTOECDYSONES AND DERIVATIVES THEREOF FOR USE IN TREATING DISORDERED RESPIRATORY FUNCTION ON VIRAL INFECTION
    Publication number: 20230128105
    Abstract: Disclosed are phytoecdysones and semisynthetic derivatives of phytoecdysones, intended to be used in treating impairment of the respiratory function in mammals, in particular in the context of a viral infection and more particularly during an infection by a coronavirus.
    Type: Application
    Filed: March 24, 2021
    Publication date: April 27, 2023
    Inventors: Pierre DILDA, René LAFONT, Stanislas VEILLET, Samuel AGUS, Waly DIOH, Serge CAMELO, Mathilde LATIL, Mounia CHABANE DE SAINT AUBIN, Cendrine TOURETTE
  • CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES
    Publication number: 20230089459
    Abstract: Disclosed is chemical compounds C that are derivatives of norbixin and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal pigment epithelium and more particularly in the context of age-related macular degeneration (AMD) and Stargardt's disease.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 23, 2023
    Inventors: Laurence DINAN, René LAFONT, Pierre DILDA, Serge CAMELO, Valérie FONTAINE, Christine BALDUCCI, Elodie MONTEIRO, Louis GUIBOUT, Mathilde LATIL, José-Alain SAHEL, Stanislas VEILLET